kymera therapeutics presents new preclinical ibd data for kt 579 a first in class oral irf5 degrader at digestive disease week

TAX_DISEASE_DISEASETAX_FNCACT_CANDIDATESTAX_WORLDMAMMALS_HUMANTAX_DISEASE_BODY_WEIGHT

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.